$ABBV Headlines AbbVie's stock rallies 1.8%, l
Post# of 89377
Posted On: 12/27/2014 12:05:46 PM
$ABBV Headlines
AbbVie's stock rallies 1.8%, leads S&P 500 gainers 9:34 a.m. Dec. 24, 2014 - Tomi Kilgore
Health-care sector taking a broad beating as pricing fears grow 2:39 p.m. Dec. 23, 2014 - Tomi Kilgore
Steelcase shares slide as revenue comes in light 5:42 p.m. Dec. 22, 2014 - MarketWatch
S&P 500, Dow industrials close at records 4:41 p.m. Dec. 22, 2014 - Sara Sjolin
Stock market may wish investors a wary Christmas 8:19 a.m. Dec. 22, 2014 - Shawn Langlois
Express Scripts picks AbbVie over Gilead for hepatitis C drug 7:45 a.m. Dec. 22, 2014 - Joseph Walker
FDA approves AbbVie’s hepatitis treatment 3:33 p.m. Dec. 19, 2014 - Peter Loftus
AbbVie's stock gains 0.8% after FDA approval of hepatitis C treatment 3:21 p.m. Dec. 19, 2014 - Tomi Kilgore
Which stocks the billionaires are buying — and selling 1:32 p.m. Dec. 12, 2014 - The Trading Deck
Paulson takes stake in Abbvie, adds to Shire holdings 6:46 p.m. Nov. 14, 2014 - MarketWatch
Obama considering Lazard banker for Treasury post 4:20 p.m. Nov. 12, 2014 - Victoria McGrane
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Merck, Dendreon miss out on health-care rally 12:39 p.m. Nov. 10, 2014 - Russ Britt
S&P 500, Dow close at record levels 4:16 p.m. Oct. 31, 2014 - Barbara Kollmeyer
Apple rallies to record high; LinkedIn jumps 11:05 a.m. Oct. 31, 2014 - Sue Chang
AbbVie stock up 3.6% at $63.38 9:32 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie shares up 4% in premarket trade 8:52 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie raises outlook as profit, sales beat 8:26 a.m. Oct. 31, 2014 - MarketWatch.com
AbbVie shares up 2% as profit, sales beat estimates 8:00 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie prior FY EPS outlook was $3.06 to $3.16 7:54 a.m. Oct. 31, 2014 - Ciara Linnane
Barron’s 10 Favorite Stocks for 2015 12:51 a.m. Today - Barrons.com
IBD 50: Biotechs Hammered, Then Find Support 5:27 p.m. Dec. 26, 2014 - Investors Business Daily
Seeking Alpha's Biotech Weekly: AbbVie Slaps Gilead, Achillion's 'Nuc' Power, And More 4:00 p.m. Dec. 26, 2014 - Seeking Alpha
Novartis' Alcon's Travatan Obtains Label Expansion in the EU - Analyst Blog 3:05 p.m. Dec. 26, 2014 - Zacks.com
Roche' (RHHBY) Blood Cancer Drug Gazyva's Label Updated - Analyst Blog 2:50 p.m. Dec. 26, 2014 - Zacks.com
4 Potential Blockbuster Drugs The FDA Just Approved 11:35 a.m. Dec. 26, 2014 - Investors Business Daily
After Gilead Sciences, Is it Time to Sell Biotech Stocks? - Analyst Blog 9:25 a.m. Dec. 26, 2014 - Zacks.com
Endo and BioDelivery Sciences submit NDA for transmucosal pain med 12:41 p.m. Dec. 25, 2014 - Seeking Alpha
Biotech Stocks Take A Beating, But Find Support 3:56 p.m. Dec. 24, 2014 - Investors Business Daily
Biotech Stock Roundup: AbbVie's HCV Treatment Approved, ImmunoGen Plunges on Data - Analyst Blog 9:48 a.m. Dec. 24, 2014 - Zacks.com
Gilead, Abbvie, Express Scripts, And Biotech Industry Turmoil Seen By Market-Makers 9:33 a.m. Dec. 24, 2014 - Seeking Alpha
Gilead Feels The Heat Of Competition 7:59 a.m. Dec. 24, 2014 - Seeking Alpha
Dow Tops 18000 7:50 p.m. Dec. 23, 2014 - The Wall Street Journal Interactive Edition
Express Scripts (ESRX) Picks AbbVie's Hepatitis C Drug - Analyst Blog 4:50 p.m. Dec. 23, 2014 - Zacks.com
AbbVie Puts The Hurt On Gilead Sciences, Closes Exclusive Deal With Express Scripts 4:41 p.m. Dec. 23, 2014 - Seeking Alpha
Dow Reaches Record Close as Santa Claus Rally Hits Day 5 4:04 p.m. Dec. 23, 2014 - TheStreet.com
Investors Should Stay Long Stocks as Market Continues Hitting Highs 3:01 p.m. Dec. 23, 2014 - TheStreet.com
Dow, S&P 500 Near Session Highs After GDP Growth Smashes Expectations 2:25 p.m. Dec. 23, 2014 - TheStreet.com
Gilead Sciences Plunges for Second Day In A Row: What Wall Street's Saying 1:48 p.m. Dec. 23, 2014 - TheStreet.com
Dow Crosses 18,000 for First Time on GDP Surge 11:06 a.m. Dec. 23, 2014 - InvestorPlace.com
Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 325400 8:15 a.m. Dec. 23, 2014 - PR Newswire - PRF
AbbVie to Present at Goldman Sachs Healthcare CEOs Unscripted Conference 8:00 a.m. Dec. 23, 2014 - PR Newswire - PRF
Pharma Deals Watch: Coverage Initiated on AstraZeneca, Advaxis, Radius Health, Cubist and AbbVie 9:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
Express Scripts and AbbVie Make Hepatitis C Cure Available to Millions of Patients in Need 7:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines 9:10 a.m. Dec. 12, 2014 - PR Newswire - PRF
AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting 8:15 p.m. Dec. 7, 2014 - PR Newswire - PRF
Gardy & Notis LLP Issues Notice Of The Filing Of A Securities Class Action Against AbbVie And Its Chief Executive Officer 4:00 p.m. Nov. 26, 2014 - PR Newswire - PRF
CHMP Grants Positive Opinions of AbbVie's VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe 8:00 a.m. Nov. 21, 2014 - PR Newswire - PRF
AbbVie to Present at Jefferies 2014 Global Healthcare Conference 7:00 a.m. Nov. 17, 2014 - PR Newswire - PRF
AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology 4:48 p.m. Nov. 14, 2014 - PR Newswire - PRF
AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014 9:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014 8:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
Infinity Reports Third Quarter 2014 Financial Results and Provides Company Update 4:01 p.m. Nov. 6, 2014 - BusinessWire - BZX
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries 8:50 a.m. Nov. 6, 2014 - PR Newswire - PRF
ABBVIE (ABBV) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating AbbVie Inc. For Potential Securities Fraud and Breach of Fiduciary Duty 8:03 a.m. Nov. 5, 2014 - BusinessWire - BZX
AbbVie to Present at Credit Suisse 2014 Healthcare Conference 8:00 a.m. Nov. 5, 2014 - PR Newswire - PRF
ABBVIE INC. ALERT -- Andrews & Springer LLC is Investigating AbbVie Inc. for Potential Securities Fraud and Breach of Fiduciary Duty 8:09 a.m. Nov. 3, 2014 - GlobeNewswire
Myriad and AbbVie Sign Expanded Agreement for Tumor BRACAnalysis CDx(TM) 7:05 a.m. Nov. 3, 2014 - GlobeNewswire
CMK Select Recognized as Women's Business Enterprise 10:45 a.m. Oct. 31, 2014 - Marketwired
AbbVie Reports Third-Quarter 2014 Financial Results 7:49 a.m. Oct. 31, 2014 - PR Newswire - PRF
AbbVie's stock rallies 1.8%, leads S&P 500 gainers 9:34 a.m. Dec. 24, 2014 - Tomi Kilgore
Health-care sector taking a broad beating as pricing fears grow 2:39 p.m. Dec. 23, 2014 - Tomi Kilgore
Steelcase shares slide as revenue comes in light 5:42 p.m. Dec. 22, 2014 - MarketWatch
S&P 500, Dow industrials close at records 4:41 p.m. Dec. 22, 2014 - Sara Sjolin
Stock market may wish investors a wary Christmas 8:19 a.m. Dec. 22, 2014 - Shawn Langlois
Express Scripts picks AbbVie over Gilead for hepatitis C drug 7:45 a.m. Dec. 22, 2014 - Joseph Walker
FDA approves AbbVie’s hepatitis treatment 3:33 p.m. Dec. 19, 2014 - Peter Loftus
AbbVie's stock gains 0.8% after FDA approval of hepatitis C treatment 3:21 p.m. Dec. 19, 2014 - Tomi Kilgore
Which stocks the billionaires are buying — and selling 1:32 p.m. Dec. 12, 2014 - The Trading Deck
Paulson takes stake in Abbvie, adds to Shire holdings 6:46 p.m. Nov. 14, 2014 - MarketWatch
Obama considering Lazard banker for Treasury post 4:20 p.m. Nov. 12, 2014 - Victoria McGrane
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Merck, Dendreon miss out on health-care rally 12:39 p.m. Nov. 10, 2014 - Russ Britt
S&P 500, Dow close at record levels 4:16 p.m. Oct. 31, 2014 - Barbara Kollmeyer
Apple rallies to record high; LinkedIn jumps 11:05 a.m. Oct. 31, 2014 - Sue Chang
AbbVie stock up 3.6% at $63.38 9:32 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie shares up 4% in premarket trade 8:52 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie raises outlook as profit, sales beat 8:26 a.m. Oct. 31, 2014 - MarketWatch.com
AbbVie shares up 2% as profit, sales beat estimates 8:00 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie prior FY EPS outlook was $3.06 to $3.16 7:54 a.m. Oct. 31, 2014 - Ciara Linnane
Barron’s 10 Favorite Stocks for 2015 12:51 a.m. Today - Barrons.com
IBD 50: Biotechs Hammered, Then Find Support 5:27 p.m. Dec. 26, 2014 - Investors Business Daily
Seeking Alpha's Biotech Weekly: AbbVie Slaps Gilead, Achillion's 'Nuc' Power, And More 4:00 p.m. Dec. 26, 2014 - Seeking Alpha
Novartis' Alcon's Travatan Obtains Label Expansion in the EU - Analyst Blog 3:05 p.m. Dec. 26, 2014 - Zacks.com
Roche' (RHHBY) Blood Cancer Drug Gazyva's Label Updated - Analyst Blog 2:50 p.m. Dec. 26, 2014 - Zacks.com
4 Potential Blockbuster Drugs The FDA Just Approved 11:35 a.m. Dec. 26, 2014 - Investors Business Daily
After Gilead Sciences, Is it Time to Sell Biotech Stocks? - Analyst Blog 9:25 a.m. Dec. 26, 2014 - Zacks.com
Endo and BioDelivery Sciences submit NDA for transmucosal pain med 12:41 p.m. Dec. 25, 2014 - Seeking Alpha
Biotech Stocks Take A Beating, But Find Support 3:56 p.m. Dec. 24, 2014 - Investors Business Daily
Biotech Stock Roundup: AbbVie's HCV Treatment Approved, ImmunoGen Plunges on Data - Analyst Blog 9:48 a.m. Dec. 24, 2014 - Zacks.com
Gilead, Abbvie, Express Scripts, And Biotech Industry Turmoil Seen By Market-Makers 9:33 a.m. Dec. 24, 2014 - Seeking Alpha
Gilead Feels The Heat Of Competition 7:59 a.m. Dec. 24, 2014 - Seeking Alpha
Dow Tops 18000 7:50 p.m. Dec. 23, 2014 - The Wall Street Journal Interactive Edition
Express Scripts (ESRX) Picks AbbVie's Hepatitis C Drug - Analyst Blog 4:50 p.m. Dec. 23, 2014 - Zacks.com
AbbVie Puts The Hurt On Gilead Sciences, Closes Exclusive Deal With Express Scripts 4:41 p.m. Dec. 23, 2014 - Seeking Alpha
Dow Reaches Record Close as Santa Claus Rally Hits Day 5 4:04 p.m. Dec. 23, 2014 - TheStreet.com
Investors Should Stay Long Stocks as Market Continues Hitting Highs 3:01 p.m. Dec. 23, 2014 - TheStreet.com
Dow, S&P 500 Near Session Highs After GDP Growth Smashes Expectations 2:25 p.m. Dec. 23, 2014 - TheStreet.com
Gilead Sciences Plunges for Second Day In A Row: What Wall Street's Saying 1:48 p.m. Dec. 23, 2014 - TheStreet.com
Dow Crosses 18,000 for First Time on GDP Surge 11:06 a.m. Dec. 23, 2014 - InvestorPlace.com
Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 325400 8:15 a.m. Dec. 23, 2014 - PR Newswire - PRF
AbbVie to Present at Goldman Sachs Healthcare CEOs Unscripted Conference 8:00 a.m. Dec. 23, 2014 - PR Newswire - PRF
Pharma Deals Watch: Coverage Initiated on AstraZeneca, Advaxis, Radius Health, Cubist and AbbVie 9:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
Express Scripts and AbbVie Make Hepatitis C Cure Available to Millions of Patients in Need 7:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines 9:10 a.m. Dec. 12, 2014 - PR Newswire - PRF
AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting 8:15 p.m. Dec. 7, 2014 - PR Newswire - PRF
Gardy & Notis LLP Issues Notice Of The Filing Of A Securities Class Action Against AbbVie And Its Chief Executive Officer 4:00 p.m. Nov. 26, 2014 - PR Newswire - PRF
CHMP Grants Positive Opinions of AbbVie's VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe 8:00 a.m. Nov. 21, 2014 - PR Newswire - PRF
AbbVie to Present at Jefferies 2014 Global Healthcare Conference 7:00 a.m. Nov. 17, 2014 - PR Newswire - PRF
AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology 4:48 p.m. Nov. 14, 2014 - PR Newswire - PRF
AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014 9:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014 8:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
Infinity Reports Third Quarter 2014 Financial Results and Provides Company Update 4:01 p.m. Nov. 6, 2014 - BusinessWire - BZX
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries 8:50 a.m. Nov. 6, 2014 - PR Newswire - PRF
ABBVIE (ABBV) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating AbbVie Inc. For Potential Securities Fraud and Breach of Fiduciary Duty 8:03 a.m. Nov. 5, 2014 - BusinessWire - BZX
AbbVie to Present at Credit Suisse 2014 Healthcare Conference 8:00 a.m. Nov. 5, 2014 - PR Newswire - PRF
ABBVIE INC. ALERT -- Andrews & Springer LLC is Investigating AbbVie Inc. for Potential Securities Fraud and Breach of Fiduciary Duty 8:09 a.m. Nov. 3, 2014 - GlobeNewswire
Myriad and AbbVie Sign Expanded Agreement for Tumor BRACAnalysis CDx(TM) 7:05 a.m. Nov. 3, 2014 - GlobeNewswire
CMK Select Recognized as Women's Business Enterprise 10:45 a.m. Oct. 31, 2014 - Marketwired
AbbVie Reports Third-Quarter 2014 Financial Results 7:49 a.m. Oct. 31, 2014 - PR Newswire - PRF
(0)
(0)